Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02101034 · ClinicalTrials.gov registry record · Phase 1
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT02101034 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 96 participants.
The verdict
NCT02101034, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this Phase I/II study is to define the maximum tolerated dose of PD 0332991 given with cetuximab and evaluated the side effects of the combination.
Interventions
- BIOLOGICAL Cetuximab
- DRUG PD 0332991
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2014-06-17 |
| Est. Completion | 2023-11-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02101034
The ClinicalTrials.gov registry entry for NCT02101034 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT02101034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02101034 about?
NCT02101034 is a clinical study titled "PD 0332991 and Cetuximab in Patients With Incurable SCCHN". The purpose of this Phase I/II study is to define the maximum tolerated dose of PD 0332991 given with cetuximab and evaluated the side effects of the combination.
What is the current status of trial NCT02101034?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2014-06-17. Estimated completion is 2023-11-10.
What interventions are being tested in trial NCT02101034?
The interventions under investigation include: Cetuximab (BIOLOGICAL), PD 0332991 (DRUG).
Who is sponsoring clinical trial NCT02101034?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.